We are live on ! Find out more
KRTX

Karuna Therapeutics, Inc. Common Stock

Delisted

KRTX was delisted on the 15th of March, 2024.

143 hedge funds and large institutions have $2.19B invested in Karuna Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $17.2M | Put options by funds: $7.32M

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

69% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 16

40% more capital invested

Capital invested by funds: $1.56B → $2.19B (+$629M)

8% more funds holding

Funds holding: 132143 (+11)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

Holders
143
Holders Change
+11
Holders Change %
+8.33%
% of All Funds
2.53%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
27
Increased
48
Reduced
46
Closed
16
Calls
$17.2M
Puts
$7.32M
Net Calls
+$9.89M
Net Calls Change
+$12.8M
Name Holding Trade Value Shares
Change
Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$14.3M +$773K +8,343 +6%
FLAM
27
First Light Asset Management
Minnesota
$14M +$852K +9,200 +7%
HRCM
28
Hood River Capital Management
Florida
$13.7M +$184K +1,981 +1%
Wellington Management Group
29
Wellington Management Group
Massachusetts
$13.5M +$12.3M +133,031 New
Holocene Advisors
30
Holocene Advisors
New York
$13.2M +$12.1M +130,257 New
LGM
31
Logos Global Management
California
$12.2M +$11.1M +120,000 New
Charles Schwab
32
Charles Schwab
California
$10.9M +$159K +1,719 +2%
MWNA
33
Marshall Wace North America
New York
$8.79M
TCM
34
Tekla Capital Management
Massachusetts
$8.66M +$4.02M +43,409 +104%
Deutsche Bank
35
Deutsche Bank
Germany
$8.07M +$409K +4,417 +6%
MS
36
Maven Securities
Jersey
$7.77M +$6.95M +75,000 New
BBA
37
Baker Bros. Advisors
New York
$7.11M -$724K -7,810 -10%
Impax Asset Management Group
38
Impax Asset Management Group
United Kingdom
$7.01M +$756K +8,157 +13%
First Manhattan
39
First Manhattan
New York
$6.79M
Bank of New York Mellon
40
Bank of New York Mellon
New York
$6.59M -$161K -1,738 -3%
ACM
41
Atika Capital Management
New York
$6.5M -$880K -9,500 -13%
PCM
42
Pentwater Capital Management
Florida
$6.09M -$926K -10,000 -14%
Millennium Management
43
Millennium Management
New York
$5.77M +$1.01M +10,935 +24%
OIA
44
OneDigital Investment Advisors
Kansas
$5.55M -$157K -1,690 -3%
Axa
45
Axa
France
$5.37M +$197K +2,126 +4%
SG Americas Securities
46
SG Americas Securities
New York
$5.34M +$1.86M +20,046 +62%
Man Group
47
Man Group
United Kingdom
$5.21M +$288K +3,105 +6%
AA
48
ALPS Advisors
Colorado
$4.89M +$1.31M +14,170 +42%
AllianceBernstein
49
AllianceBernstein
Tennessee
$4.23M +$1.03M +11,140 +36%
Barclays
50
Barclays
United Kingdom
$4.14M +$3.01M +32,476 +394%

KRTX Hedge Fund Activity: Q4 2020 in Review

143 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2020, worth a combined $2.19B — up 40% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new KRTX positions and 16 closed out — a net gain of 11 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $62.2M. The largest seller was Fidelity International, cutting an estimated $62.2M.

  • 143 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2020, up from 132 in Q3 2020.
  • Funds reported $2.19B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2020, up 40% quarter-over-quarter.
  • 27 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +11 holders.
  • The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2020 was Fidelity Investments, an estimated $62.2M added.
  • The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2020 was Fidelity International, an estimated $62.2M sold.

Based on aggregated 13F filings for Q4 2020.